Please use this identifier to cite or link to this item:
Title: Metastatic Thymic Carcinoma with Long Survival After Treatment with Sunitinib.
Issue Date: 14-Jul-2018
Citation: Cureus.2018 Jul;(10)7:e2982
Abstract: Thymic carcinomas are the most aggressive histological subtype of thymic tumors with limited data to guide correct management. No standard treatments are available for patients with advanced thymic carcinoma after progressing while on platinum-based chemotherapy. We present a case of a patient with metastatic thymic carcinoma with an unusual response and favorable evolution after receiving treatment with sunitinib, obtaining a progression-free survival of 23 months, much higher than reported to date. We review the literature on the efficacy of sunitinib in metastatic thymic carcinoma after progression to first-line treatment with platinum combinations.
PMID: 30237943
Rights: openAccess
ISSN: 2168-8184
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC6141057.pdf1.64 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.